SUBRETINAL FLUID ASSOCIATED WITH PEMIGATINIB THERAPY FOR CHOLANGIOCARCINOMA: A CASE REPORT AND LITERATURE REVIEW.

PURPOSE

To describe the retinal findings associated with pemigatinib, an oral competitive inhibitor of fibroblast growth factor receptor approved for the treatment of cholangiocarcinoma.

METHODS

A case report is presented, and a literature review was performed, revealing only two prior reported cases of pemigatinib-mediated subretinal fluid.

RESULTS

A 72-year-old woman presented with transient visual symptoms while on pemigatinib for the treatment of cholangiocarcinoma. Optical coherence tomography revealed subfoveal subretinal fluid bilaterally that resolved during a drug holiday; however, it fluctuated throughout her treatment course. She remained on pemigatinib for 10 months without other ocular sequelae.

CONCLUSION

This is one of the few reported cases of pemigatinib-related retinopathy, which further supports the self-limited and benign nature of subretinal fluid associated with fibroblast growth factor receptor inhibitors.